董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Graydon Bensler | 男 | Chief Executive Officer and Chief Financial Officer and Director | 34 | 69.78万美元 | 303.64 | 2026-06-05 |
| Jeffrey Parry | 男 | Independent Director | 64 | 5.50万美元 | 0.0002 | 2026-06-05 |
| Juliana Daley | 女 | Independent Director | 36 | 5.50万美元 | 0.0002 | 2026-06-05 |
| Braeden Lichti | 男 | Director and Non-Executive Chairman of the Board | 41 | 32.88万美元 | 333.65 | 2026-06-05 |
| George Kovalyov | 男 | Independent Director | 39 | 5.50万美元 | 未持股 | 2026-06-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Graydon Bensler | 男 | Chief Executive Officer and Chief Financial Officer and Director | 34 | 69.78万美元 | 303.64 | 2026-06-05 |
董事简历
中英对照 | 中文 | 英文- Graydon Bensler
-
Graydon Bensler，自Elevai Labs，Inc.成立以来一直担任Elevai Labs，Inc.的首席财务官。Bensler先生是一名金融专业人士和分析师，在私营企业和美国/加拿大上市公司的金融咨询和管理方面拥有超过七年的经验，并且是一名特许金融分析师（CFA）。2017年，本斯勒与他人共同创立了一家教育科技课程管理和安排公司，该公司被植入加拿大和美国的学术学校。从2017年到2019年，本斯勒在一家领先的加拿大投资者关系公司担任客户经理，在那里他代表各行各业的上市公司，直接与投资银行、投资经纪人以及公司高管和董事合作。在任职期间，本斯勒创建并传达了有关其客户在市场中的战略地位的信息，并成功地指导了多家公司通过多次融资。从2019年到2021年，本斯勒在加拿大精品投行Evans & Evans担任高级助理，负责加拿大和美国公司的估值和上市交易。在担任这一职务期间，本斯勒先生对资本市场、上市公司合规要求有了很深的了解，并定期与监管机构、审计员、董事会和执行管理层进行交流。自2020年以来，本斯勒还担任上市公司Health Logic Interactive Inc.（TSXv：CHIP）的董事。我们相信，Bensler先生过去担任Elevai Labs，Inc. 首席财务官的经验，他对银行和金融咨询行业的熟悉，以及他曾在类似情况的公司担任客户经理，使他成为Elevai Labs，Inc.公司的合格董事。本斯勒在西安大略大学获得管理和组织研究学士学位，专攻金融，是CFA特许持有人。
Graydon Bensler has served as Pmgc Holdings Inc.'s Chief Executive Officer since June 2024 and Chief Financial Officer since inception and a director since June 9, 2020. Mr. Bensler is a financial professional and analyst with over eight years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a CFA Charterholder (CFA). Mr. Bensler is the founder and sole owner of GB Capital Ltd, a privately held holding company he founded in 2019 and which company is engaged in capital markets advisory, financial consulting, and management. In 2017, Mr. Bensler co founded an education technology curriculum management and scheduling company that was implemented in academic schools in Canada and the United States. From 2017 to 2019, Mr. Bensler was an account manager at a leading Canadian investor relations firm where he represented publicly traded companies across a wide range of sectors and worked directly with investment banks, investment brokers and company executives and directors. During his tenure at this investor relations firm, Mr. Bensler created and conveyed messaging about his clients' strategic position in the market and successfully guided several companies through multiple financings. From 2019 to 2021, Mr. Bensler was a Senior Associate at Evans & Evans, a Canadian boutique investment banking firm where he led valuations and going public transactions for Canadian and United States companies. In this capacity, Mr. Bensler gained strong knowledge of the capital markets, public company compliance requirements, and regularly interfaced with regulators, auditors, board and executive management. - Graydon Bensler，自Elevai Labs，Inc.成立以来一直担任Elevai Labs，Inc.的首席财务官。Bensler先生是一名金融专业人士和分析师，在私营企业和美国/加拿大上市公司的金融咨询和管理方面拥有超过七年的经验，并且是一名特许金融分析师（CFA）。2017年，本斯勒与他人共同创立了一家教育科技课程管理和安排公司，该公司被植入加拿大和美国的学术学校。从2017年到2019年，本斯勒在一家领先的加拿大投资者关系公司担任客户经理，在那里他代表各行各业的上市公司，直接与投资银行、投资经纪人以及公司高管和董事合作。在任职期间，本斯勒创建并传达了有关其客户在市场中的战略地位的信息，并成功地指导了多家公司通过多次融资。从2019年到2021年，本斯勒在加拿大精品投行Evans & Evans担任高级助理，负责加拿大和美国公司的估值和上市交易。在担任这一职务期间，本斯勒先生对资本市场、上市公司合规要求有了很深的了解，并定期与监管机构、审计员、董事会和执行管理层进行交流。自2020年以来，本斯勒还担任上市公司Health Logic Interactive Inc.（TSXv：CHIP）的董事。我们相信，Bensler先生过去担任Elevai Labs，Inc. 首席财务官的经验，他对银行和金融咨询行业的熟悉，以及他曾在类似情况的公司担任客户经理，使他成为Elevai Labs，Inc.公司的合格董事。本斯勒在西安大略大学获得管理和组织研究学士学位，专攻金融，是CFA特许持有人。
- Graydon Bensler has served as Pmgc Holdings Inc.'s Chief Executive Officer since June 2024 and Chief Financial Officer since inception and a director since June 9, 2020. Mr. Bensler is a financial professional and analyst with over eight years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a CFA Charterholder (CFA). Mr. Bensler is the founder and sole owner of GB Capital Ltd, a privately held holding company he founded in 2019 and which company is engaged in capital markets advisory, financial consulting, and management. In 2017, Mr. Bensler co founded an education technology curriculum management and scheduling company that was implemented in academic schools in Canada and the United States. From 2017 to 2019, Mr. Bensler was an account manager at a leading Canadian investor relations firm where he represented publicly traded companies across a wide range of sectors and worked directly with investment banks, investment brokers and company executives and directors. During his tenure at this investor relations firm, Mr. Bensler created and conveyed messaging about his clients' strategic position in the market and successfully guided several companies through multiple financings. From 2019 to 2021, Mr. Bensler was a Senior Associate at Evans & Evans, a Canadian boutique investment banking firm where he led valuations and going public transactions for Canadian and United States companies. In this capacity, Mr. Bensler gained strong knowledge of the capital markets, public company compliance requirements, and regularly interfaced with regulators, auditors, board and executive management.
- Jeffrey Parry
-
Jeffrey Parry，NorthStrike Acquisition Corp I.的董事。自1998年1月以来，Parry先生一直担任Mystic Marine Advisors，LLC的合伙人，该公司是一家战略咨询公司，其客户包括麦格理银行、Alix Partners LLP和Torm PLC。自2010年5月起，担任国际海运干散货航运服务提供商Globus Maritime Limited（纳斯达克：GLBS）的非执行董事和审计委员会成员。从2012年到2018年，帕里先生担任TBS Shipping的执行主席，曾被美国银行牵头的信贷委员会任命，负责管理47艘船队。2008年至2009年，他还曾担任国际航运上市公司Aries Maritime Transport Limited（纳斯达克：RAMS）的首席执行官。Parry先生在哥伦比亚商学院获得会计和金融工商管理硕士学位，在布朗大学获得英美文学文学学士学位。帕里先生的职业生涯以战略咨询、重组和上市公司董事会服务为中心，领导工作跨越资本市场交易和数字资产领域。
Jeffrey Parry, Northstrive Acquisition Corp I.'s Director. Since January 1998, Mr. Parry has served as a Partner of Mystic Marine Advisors, LLC, a strategic advisory firm whose clients have included Macquarie Bank, Alix Partners LLP, and Torm PLC. Since May 2010, he has served as a Non Executive Director and Audit Committee member of Globus Maritime Limited (Nasdaq: GLBS), an international provider of marine dry bulk shipping services. From 2012 to 2018, Mr. Parry served as Executive Chairman of TBS Shipping, having been appointed by a Bank of America led credit committee to manage a 47 vessel fleet. From 2008 to 2009, he also served as Chief Executive Officer of Aries Maritime Transport Limited (Nasdaq: RAMS), a publicly traded international shipping company. Mr. Parry received a Master of Business Administration in Accounting and Finance from Columbia Business School and a Bachelor of Arts in English and American Literature from Brown University. Mr. Parry's career has centered on strategic advisory, restructuring, and public company board service, with leadership engagements spanning capital markets transactions and digital asset sectors. - Jeffrey Parry，NorthStrike Acquisition Corp I.的董事。自1998年1月以来，Parry先生一直担任Mystic Marine Advisors，LLC的合伙人，该公司是一家战略咨询公司，其客户包括麦格理银行、Alix Partners LLP和Torm PLC。自2010年5月起，担任国际海运干散货航运服务提供商Globus Maritime Limited（纳斯达克：GLBS）的非执行董事和审计委员会成员。从2012年到2018年，帕里先生担任TBS Shipping的执行主席，曾被美国银行牵头的信贷委员会任命，负责管理47艘船队。2008年至2009年，他还曾担任国际航运上市公司Aries Maritime Transport Limited（纳斯达克：RAMS）的首席执行官。Parry先生在哥伦比亚商学院获得会计和金融工商管理硕士学位，在布朗大学获得英美文学文学学士学位。帕里先生的职业生涯以战略咨询、重组和上市公司董事会服务为中心，领导工作跨越资本市场交易和数字资产领域。
- Jeffrey Parry, Northstrive Acquisition Corp I.'s Director. Since January 1998, Mr. Parry has served as a Partner of Mystic Marine Advisors, LLC, a strategic advisory firm whose clients have included Macquarie Bank, Alix Partners LLP, and Torm PLC. Since May 2010, he has served as a Non Executive Director and Audit Committee member of Globus Maritime Limited (Nasdaq: GLBS), an international provider of marine dry bulk shipping services. From 2012 to 2018, Mr. Parry served as Executive Chairman of TBS Shipping, having been appointed by a Bank of America led credit committee to manage a 47 vessel fleet. From 2008 to 2009, he also served as Chief Executive Officer of Aries Maritime Transport Limited (Nasdaq: RAMS), a publicly traded international shipping company. Mr. Parry received a Master of Business Administration in Accounting and Finance from Columbia Business School and a Bachelor of Arts in English and American Literature from Brown University. Mr. Parry's career has centered on strategic advisory, restructuring, and public company board service, with leadership engagements spanning capital markets transactions and digital asset sectors.
- Juliana Daley
-
Juliana Daley于2023年6月被任命为独立董事，在公共部门拥有超过11年的会计、财务总监和财务报告经验。戴利曾在美国和加拿大的多个行业工作过。自2021年7月起，戴利女士担任Anavex Life Sciences Corp.（纳斯达克股票代码：AVXL）的会计经理，该公司是一家临床阶段的生物制药公司，总部位于纽约州纽约市，专注于开发治疗使人衰弱的神经退行性疾病和神经发育疾病的方法。此外，在2021年8月至2022年7月，她在Vegano Foods（CSE：VAGN）2022年2月首次公开发行期间担任独立董事和审计委员会主席。2015年10月至2021年7月，Daley女士通过在会计公司Treewalk（前身为ACM Management，Inc.）任职，担任美国和加拿大多家上市公司的财务报告和咨询服务经理。在Treewalk，Daley女士协助客户满足其季度和年度报告要求，包括编制完整的财务报告包和从头到尾管理保证业务。在Treewalk，她还担任Makena Resources Inc.（CSE：MKNA）（2018年4月至2019年4月）和Naked Brand Group Inc.（NASDAQ：NAKD）（2018年3月至2018年6月）的首席财务官，直到2019年4月和2018年6月这两家公司的预期合并完成。2011年9月至2015年4月，Daley女士受雇于Naked Brand Group Inc.，在该公司的会计部门工作，从2013年8月起担任财务总监，直到2015年4月离职。她还负责协助各种业务职能，包括EDI实施、ERP实施、库存管理、信息技术和办公室管理。从2021年7月至今，Daley女士担任Anavex Life Sciences的会计经理，协助完成所有内部报告、预算编制和运营事项，如年度SOX审计、季度审查、IT审计和年度审计。戴利在上市公司财务会计方面的专业知识，以及她曾在美国上市公司担任首席财务官和财务总监的经历，使她成为Elevai Labs，Inc.的合格董事候选人。2015年9月，戴利通过注册会计师西部商学院完成了共同期末考试（CFE），并于2016年5月被指定为董事。她还拥有不列颠哥伦比亚省阿伯茨福德的弗雷泽河谷大学会计和经济学学士学位。
Juliana Daley was appointed as an independent director in June 2023 and holds over eleven years of accounting, controller, and financial reporting experience in the public sector. Ms. Daley has worked a variety of industries in both the United States and Canada. Since July 2021, Ms. Daley has served as Manager of Accounting at Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical stage biopharmaceutical company based in New York, NY that is focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. In addition, from August 2021 to July 2022, she served as an independent director and audit committee chair to Vegano Foods (CSE: VAGN) during Vegano Food's initial public offering in February 2022. From October 2015 to July 2021, Ms. Daley was a Manager of Financial Reporting and Advisory Services to various public companies in the United States and Canada, through her position with the accounting firm, Treewalk (previously ACM Management, Inc.). At Treewalk Ms. Daley assisted clients in meeting their quarterly and annual reporting requirements including the preparation of complete financial reporting packages and managing assurance engagements from start to finish. At Treewalk, she also served as chief financial officer to Makena Resources Inc. (CSE: MKNA) (April 2018 April 2019) and Naked Brand Group Inc. (NASDAQ: NAKD) (March 2018 June 2018) until the completion of their prospective mergers in April 2019 and June 2018, respectively. From September 2011 to April 2015, Ms. Daley was employed with Naked Brand Group Inc., where she worked in the accounting department, serving as controller from August 2013 until her departure in April 2015, and where she was also responsible for assisting in various operational functions including EDI implementation, ERP implementation, inventory management, information technology and office administration. From July 2021 to present, Ms. Daley has acted as manager of accounting at Anavex Life Sciences where she assists to in the finalization of all internal reporting, budgeting, and operational matters such as annual SOX audits, quarterly reviews, IT audits, and annual audits. - Juliana Daley于2023年6月被任命为独立董事，在公共部门拥有超过11年的会计、财务总监和财务报告经验。戴利曾在美国和加拿大的多个行业工作过。自2021年7月起，戴利女士担任Anavex Life Sciences Corp.（纳斯达克股票代码：AVXL）的会计经理，该公司是一家临床阶段的生物制药公司，总部位于纽约州纽约市，专注于开发治疗使人衰弱的神经退行性疾病和神经发育疾病的方法。此外，在2021年8月至2022年7月，她在Vegano Foods（CSE：VAGN）2022年2月首次公开发行期间担任独立董事和审计委员会主席。2015年10月至2021年7月，Daley女士通过在会计公司Treewalk（前身为ACM Management，Inc.）任职，担任美国和加拿大多家上市公司的财务报告和咨询服务经理。在Treewalk，Daley女士协助客户满足其季度和年度报告要求，包括编制完整的财务报告包和从头到尾管理保证业务。在Treewalk，她还担任Makena Resources Inc.（CSE：MKNA）（2018年4月至2019年4月）和Naked Brand Group Inc.（NASDAQ：NAKD）（2018年3月至2018年6月）的首席财务官，直到2019年4月和2018年6月这两家公司的预期合并完成。2011年9月至2015年4月，Daley女士受雇于Naked Brand Group Inc.，在该公司的会计部门工作，从2013年8月起担任财务总监，直到2015年4月离职。她还负责协助各种业务职能，包括EDI实施、ERP实施、库存管理、信息技术和办公室管理。从2021年7月至今，Daley女士担任Anavex Life Sciences的会计经理，协助完成所有内部报告、预算编制和运营事项，如年度SOX审计、季度审查、IT审计和年度审计。戴利在上市公司财务会计方面的专业知识，以及她曾在美国上市公司担任首席财务官和财务总监的经历，使她成为Elevai Labs，Inc.的合格董事候选人。2015年9月，戴利通过注册会计师西部商学院完成了共同期末考试（CFE），并于2016年5月被指定为董事。她还拥有不列颠哥伦比亚省阿伯茨福德的弗雷泽河谷大学会计和经济学学士学位。
- Juliana Daley was appointed as an independent director in June 2023 and holds over eleven years of accounting, controller, and financial reporting experience in the public sector. Ms. Daley has worked a variety of industries in both the United States and Canada. Since July 2021, Ms. Daley has served as Manager of Accounting at Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical stage biopharmaceutical company based in New York, NY that is focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. In addition, from August 2021 to July 2022, she served as an independent director and audit committee chair to Vegano Foods (CSE: VAGN) during Vegano Food's initial public offering in February 2022. From October 2015 to July 2021, Ms. Daley was a Manager of Financial Reporting and Advisory Services to various public companies in the United States and Canada, through her position with the accounting firm, Treewalk (previously ACM Management, Inc.). At Treewalk Ms. Daley assisted clients in meeting their quarterly and annual reporting requirements including the preparation of complete financial reporting packages and managing assurance engagements from start to finish. At Treewalk, she also served as chief financial officer to Makena Resources Inc. (CSE: MKNA) (April 2018 April 2019) and Naked Brand Group Inc. (NASDAQ: NAKD) (March 2018 June 2018) until the completion of their prospective mergers in April 2019 and June 2018, respectively. From September 2011 to April 2015, Ms. Daley was employed with Naked Brand Group Inc., where she worked in the accounting department, serving as controller from August 2013 until her departure in April 2015, and where she was also responsible for assisting in various operational functions including EDI implementation, ERP implementation, inventory management, information technology and office administration. From July 2021 to present, Ms. Daley has acted as manager of accounting at Anavex Life Sciences where she assists to in the finalization of all internal reporting, budgeting, and operational matters such as annual SOX audits, quarterly reviews, IT audits, and annual audits.
- Braeden Lichti
-
Braeden Lichti是加拿大公民。股票期权授予Lichti先生，作为对其为发行人提供服务的补偿。
Braeden Lichti has served as Non Executive Chairman of the Board from June 21, 2024 to the present. Mr. Lichti, together with his organization NorthStrive Companies Inc, led the restructuring and repositioning of what was formerly Elevai Labs into PMGC, a diversified public holding company focused on acquiring and scaling operating businesses.Mr. Lichti has served as Chief Executive Officer of BWL Investments Ltd., a privately held investment and holding company, since its founding in 2016. He is also the Founder and Chief Executive Officer of NorthStrive Companies, Inc., a U.S. based investment and advisory firm, since 2021.From October 8, 2024 to November 17, 2025, Mr. Lichti served as a member of the Board of Directors of Qualigen Therapeutics, Inc. (NASDAQ:QLGN). During his tenure, the Company completed a $41 million private investment in public equity (PIPE) financing led by Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI), resulting in a change of control, board reconstitution, and a strategic transformation of the business toward a new operating model.Mr. Lichti has also been involved with Hydromer, Inc. (OTC:HYDI), where Northstrive Companies Inc. was an advisor and significant shareholder. During this period, the Company secured a strategic investment from jMedtech, a global medical device company, resulting in a change of control, board reconstitution, and the establishment of an expanded international platform within the medical device coatings industry.Mr. Lichti has over a decade of experience in public markets, mergers and acquisitions, capital formation, and corporate restructuring. He has been directly involved in multiple public company transactions, including initial public offerings, reverse mergers, recapitalizations, and strategic investments. - Braeden Lichti是加拿大公民。股票期权授予Lichti先生，作为对其为发行人提供服务的补偿。
- Braeden Lichti has served as Non Executive Chairman of the Board from June 21, 2024 to the present. Mr. Lichti, together with his organization NorthStrive Companies Inc, led the restructuring and repositioning of what was formerly Elevai Labs into PMGC, a diversified public holding company focused on acquiring and scaling operating businesses.Mr. Lichti has served as Chief Executive Officer of BWL Investments Ltd., a privately held investment and holding company, since its founding in 2016. He is also the Founder and Chief Executive Officer of NorthStrive Companies, Inc., a U.S. based investment and advisory firm, since 2021.From October 8, 2024 to November 17, 2025, Mr. Lichti served as a member of the Board of Directors of Qualigen Therapeutics, Inc. (NASDAQ:QLGN). During his tenure, the Company completed a $41 million private investment in public equity (PIPE) financing led by Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI), resulting in a change of control, board reconstitution, and a strategic transformation of the business toward a new operating model.Mr. Lichti has also been involved with Hydromer, Inc. (OTC:HYDI), where Northstrive Companies Inc. was an advisor and significant shareholder. During this period, the Company secured a strategic investment from jMedtech, a global medical device company, resulting in a change of control, board reconstitution, and the establishment of an expanded international platform within the medical device coatings industry.Mr. Lichti has over a decade of experience in public markets, mergers and acquisitions, capital formation, and corporate restructuring. He has been directly involved in multiple public company transactions, including initial public offerings, reverse mergers, recapitalizations, and strategic investments.
- George Kovalyov
-
George Kovalyov CPA，CA，NorthStrive Acquisition Corp I.的董事。Kovalyov先生是一名特许专业会计师（CPA，CA），在公共市场、公司财务和治理方面拥有丰富的经验。从2025年11月至今，Kovalyov先生担任Finx Group Inc.的首席财务官，该公司是一家总部位于温哥华的金融科技公司，提供汽车行业的金融和保险解决方案。2024年4月至今，任PMGC Holdings Inc.独立董事兼薪酬委员会主席、审计委员会成员。PMGC Holdings Inc.（纳斯达克：ELAB）是一家专注于现金流制造业收购的多元化控股公司。2023年8月至2025年9月，Kovalyov先生担任Hydromer，Inc.的董事，该公司是一家为医疗设备和工业应用提供亲水涂层解决方案的供应商。他此前在2021年12月至2025年11月期间，担任总部位于佛罗里达州的心脏医疗设备公司Marizyme, Inc.的首席财务官，该公司的设备获得了FDA的批准，可用于CABG手术。2020年9月至2021年12月，Kovalyov先生担任Health Logic Interactive Inc.的首席财务官，该公司是一家早期医疗设备公司，开发针对慢性肾脏疾病的即时诊断。Kovalyov先生拥有Kwantlen大学学院会计学工商管理学士学位，并于2011年获得不列颠哥伦比亚省特许会计师协会的特许会计师称号。
George Kovalyov CPA, CA, Northstrive Acquisition Corp I.'s Director. Mr. Kovalyov is a Chartered Professional Accountant (CPA, CA) with extensive experience across public markets, corporate finance, and governance. From November 2025 to the present, Mr. Kovalyov serves as Chief Financial Officer of Finx Group Inc., a Vancouver based fintech company providing finance and insurance solutions in the automotive industry. From April 2024 to the present, he serves as an independent director and Chairman of the Compensation Committee for PMGC Holdings Inc. as well as a member of its Audit Committee. PMGC Holdings Inc. (Nasdaq: ELAB) is a ), a diversified holdings company focused on cash flowing manufacturing acquisitions. From August 2023 to September 2025, Mr. Kovalyov served as a Director of Hydromer, Inc., a provider of hydrophilic coating solutions for medical devices and industrial applications. He was previously Chief Financial Officer of Marizyme, Inc., a Florida based cardiac medical device company whose device received FDA approval for use in CABG surgeries, from December 2021 to November 2025. From September 2020 to December 2021, Mr. Kovalyov served as Chief Financial Officer of Health Logic Interactive Inc., an early stage medical device company developing a point of care diagnostic for chronic kidney disease. Mr. Kovalyov holds a Bachelor of Business Administration in Accounting from Kwantlen University College and received his Chartered Accountant designation from the Institute of Chartered Accountants of British Columbia in 2011. - George Kovalyov CPA，CA，NorthStrive Acquisition Corp I.的董事。Kovalyov先生是一名特许专业会计师（CPA，CA），在公共市场、公司财务和治理方面拥有丰富的经验。从2025年11月至今，Kovalyov先生担任Finx Group Inc.的首席财务官，该公司是一家总部位于温哥华的金融科技公司，提供汽车行业的金融和保险解决方案。2024年4月至今，任PMGC Holdings Inc.独立董事兼薪酬委员会主席、审计委员会成员。PMGC Holdings Inc.（纳斯达克：ELAB）是一家专注于现金流制造业收购的多元化控股公司。2023年8月至2025年9月，Kovalyov先生担任Hydromer，Inc.的董事，该公司是一家为医疗设备和工业应用提供亲水涂层解决方案的供应商。他此前在2021年12月至2025年11月期间，担任总部位于佛罗里达州的心脏医疗设备公司Marizyme, Inc.的首席财务官，该公司的设备获得了FDA的批准，可用于CABG手术。2020年9月至2021年12月，Kovalyov先生担任Health Logic Interactive Inc.的首席财务官，该公司是一家早期医疗设备公司，开发针对慢性肾脏疾病的即时诊断。Kovalyov先生拥有Kwantlen大学学院会计学工商管理学士学位，并于2011年获得不列颠哥伦比亚省特许会计师协会的特许会计师称号。
- George Kovalyov CPA, CA, Northstrive Acquisition Corp I.'s Director. Mr. Kovalyov is a Chartered Professional Accountant (CPA, CA) with extensive experience across public markets, corporate finance, and governance. From November 2025 to the present, Mr. Kovalyov serves as Chief Financial Officer of Finx Group Inc., a Vancouver based fintech company providing finance and insurance solutions in the automotive industry. From April 2024 to the present, he serves as an independent director and Chairman of the Compensation Committee for PMGC Holdings Inc. as well as a member of its Audit Committee. PMGC Holdings Inc. (Nasdaq: ELAB) is a ), a diversified holdings company focused on cash flowing manufacturing acquisitions. From August 2023 to September 2025, Mr. Kovalyov served as a Director of Hydromer, Inc., a provider of hydrophilic coating solutions for medical devices and industrial applications. He was previously Chief Financial Officer of Marizyme, Inc., a Florida based cardiac medical device company whose device received FDA approval for use in CABG surgeries, from December 2021 to November 2025. From September 2020 to December 2021, Mr. Kovalyov served as Chief Financial Officer of Health Logic Interactive Inc., an early stage medical device company developing a point of care diagnostic for chronic kidney disease. Mr. Kovalyov holds a Bachelor of Business Administration in Accounting from Kwantlen University College and received his Chartered Accountant designation from the Institute of Chartered Accountants of British Columbia in 2011.
高管简历
中英对照 | 中文 | 英文- Graydon Bensler
Graydon Bensler，自Elevai Labs，Inc.成立以来一直担任Elevai Labs，Inc.的首席财务官。Bensler先生是一名金融专业人士和分析师，在私营企业和美国/加拿大上市公司的金融咨询和管理方面拥有超过七年的经验，并且是一名特许金融分析师（CFA）。2017年，本斯勒与他人共同创立了一家教育科技课程管理和安排公司，该公司被植入加拿大和美国的学术学校。从2017年到2019年，本斯勒在一家领先的加拿大投资者关系公司担任客户经理，在那里他代表各行各业的上市公司，直接与投资银行、投资经纪人以及公司高管和董事合作。在任职期间，本斯勒创建并传达了有关其客户在市场中的战略地位的信息，并成功地指导了多家公司通过多次融资。从2019年到2021年，本斯勒在加拿大精品投行Evans & Evans担任高级助理，负责加拿大和美国公司的估值和上市交易。在担任这一职务期间，本斯勒先生对资本市场、上市公司合规要求有了很深的了解，并定期与监管机构、审计员、董事会和执行管理层进行交流。自2020年以来，本斯勒还担任上市公司Health Logic Interactive Inc.（TSXv：CHIP）的董事。我们相信，Bensler先生过去担任Elevai Labs，Inc. 首席财务官的经验，他对银行和金融咨询行业的熟悉，以及他曾在类似情况的公司担任客户经理，使他成为Elevai Labs，Inc.公司的合格董事。本斯勒在西安大略大学获得管理和组织研究学士学位，专攻金融，是CFA特许持有人。
Graydon Bensler has served as Pmgc Holdings Inc.'s Chief Executive Officer since June 2024 and Chief Financial Officer since inception and a director since June 9, 2020. Mr. Bensler is a financial professional and analyst with over eight years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a CFA Charterholder (CFA). Mr. Bensler is the founder and sole owner of GB Capital Ltd, a privately held holding company he founded in 2019 and which company is engaged in capital markets advisory, financial consulting, and management. In 2017, Mr. Bensler co founded an education technology curriculum management and scheduling company that was implemented in academic schools in Canada and the United States. From 2017 to 2019, Mr. Bensler was an account manager at a leading Canadian investor relations firm where he represented publicly traded companies across a wide range of sectors and worked directly with investment banks, investment brokers and company executives and directors. During his tenure at this investor relations firm, Mr. Bensler created and conveyed messaging about his clients' strategic position in the market and successfully guided several companies through multiple financings. From 2019 to 2021, Mr. Bensler was a Senior Associate at Evans & Evans, a Canadian boutique investment banking firm where he led valuations and going public transactions for Canadian and United States companies. In this capacity, Mr. Bensler gained strong knowledge of the capital markets, public company compliance requirements, and regularly interfaced with regulators, auditors, board and executive management.- Graydon Bensler，自Elevai Labs，Inc.成立以来一直担任Elevai Labs，Inc.的首席财务官。Bensler先生是一名金融专业人士和分析师，在私营企业和美国/加拿大上市公司的金融咨询和管理方面拥有超过七年的经验，并且是一名特许金融分析师（CFA）。2017年，本斯勒与他人共同创立了一家教育科技课程管理和安排公司，该公司被植入加拿大和美国的学术学校。从2017年到2019年，本斯勒在一家领先的加拿大投资者关系公司担任客户经理，在那里他代表各行各业的上市公司，直接与投资银行、投资经纪人以及公司高管和董事合作。在任职期间，本斯勒创建并传达了有关其客户在市场中的战略地位的信息，并成功地指导了多家公司通过多次融资。从2019年到2021年，本斯勒在加拿大精品投行Evans & Evans担任高级助理，负责加拿大和美国公司的估值和上市交易。在担任这一职务期间，本斯勒先生对资本市场、上市公司合规要求有了很深的了解，并定期与监管机构、审计员、董事会和执行管理层进行交流。自2020年以来，本斯勒还担任上市公司Health Logic Interactive Inc.（TSXv：CHIP）的董事。我们相信，Bensler先生过去担任Elevai Labs，Inc. 首席财务官的经验，他对银行和金融咨询行业的熟悉，以及他曾在类似情况的公司担任客户经理，使他成为Elevai Labs，Inc.公司的合格董事。本斯勒在西安大略大学获得管理和组织研究学士学位，专攻金融，是CFA特许持有人。
- Graydon Bensler has served as Pmgc Holdings Inc.'s Chief Executive Officer since June 2024 and Chief Financial Officer since inception and a director since June 9, 2020. Mr. Bensler is a financial professional and analyst with over eight years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a CFA Charterholder (CFA). Mr. Bensler is the founder and sole owner of GB Capital Ltd, a privately held holding company he founded in 2019 and which company is engaged in capital markets advisory, financial consulting, and management. In 2017, Mr. Bensler co founded an education technology curriculum management and scheduling company that was implemented in academic schools in Canada and the United States. From 2017 to 2019, Mr. Bensler was an account manager at a leading Canadian investor relations firm where he represented publicly traded companies across a wide range of sectors and worked directly with investment banks, investment brokers and company executives and directors. During his tenure at this investor relations firm, Mr. Bensler created and conveyed messaging about his clients' strategic position in the market and successfully guided several companies through multiple financings. From 2019 to 2021, Mr. Bensler was a Senior Associate at Evans & Evans, a Canadian boutique investment banking firm where he led valuations and going public transactions for Canadian and United States companies. In this capacity, Mr. Bensler gained strong knowledge of the capital markets, public company compliance requirements, and regularly interfaced with regulators, auditors, board and executive management.